Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS

Chuan Xing; Chunzhu Li; Bing He

Disclosures

J Clin Endocrinol Metab. 2020;105(9) 

In This Article

Summary

The aim of this network meta-analysis is to evaluate the efficacy of GLP-1 receptor agonists, TZDs or their combination with metformin on the improvement of symptoms, sex hormone and metabolic parameters in overweight women with PCOS by comparing with metformin. Our results reveal that both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia. Metformin combined with TZDs could be particularly effective in promoting the recovery of menstruation. Metformin combined with GLP-1 receptor agonists has additional advantage in improving fasting glucose when compared with GLP-1 receptor agonists alone. TZD is inferior to metformin in decreasing BMI.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....